Following the Court of Appeals for the Federal Circuit’s denial of Regeneron’s application for injunction against Amgen earlier in October 2024, Amgen confirmed during its earnings call on 30 October 2024 that it has launched Pavblu®/aflibercept (biosimilar to Regeneron/Bayer’s Eylea®) in the US and is preparing to launch Wezlana®/ustekinumab (biosimilar to Amgen’s Stelara®) and Bekemv®/eculizumab (biosimilar to Alexion’s Soliris®) in the first and second quarters of 2025 respectively.
Amgen’s Executive Vice President of Global Commercial Operations Murdo Gordon said:
“Our biosimilar products increased 9% year-over-year in the third quarter. We have fully deployed our team in support of the recent U.S. launch of PAVBLU, a biosimilar to EYLEA. Our teams moved quickly to engage retina specialists, and we’re encouraged by the enthusiastic feedback from customers. Our teams are also ready for the upcoming U.S. launches of WEZLANA, a biosimilar to STELARA and BEKEMV, a biosimilar to Solaris, expected in the first and second quarters of 2025, respectively. Overall, our biosimilars portfolio continues to deliver attractive returns driven by our efficient business model.”